|
Tuesday, May 21, 2002 |
 |
|
7:00-8:00 AM |
Breakfast with the Experts |
|
|
Theoretical Issues in
Cost-Effectiveness Analysis
Milton Weinstein PhD, Professor, Health Policy & Management, Center
for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
N.I.C.E.
Andrew H. Briggs DPhil, Health Economics Research Centre, Institute
of Health Sciences, Oxford University, Oxford, United Kingdom
Quality of Life Research
Pennifer Erickson PhD, Co-founder, O.L.G.A, State College, PA, USA
Outcomes Research in the Pharmaceutical Industry
Marc Berger MD, Vice President, Outcomes Research & Management, Merck &
Company, Inc., West Point, PA, USA
|
|
8:00-9:30 AM |
Concurrent Podium Sessions (4
sessions) |
|
|
Study results and issues on the following topics
will be discussed.
|
METHODOLOGY ISSUES I |
|
Moderator:
David Thompson PhD, Managing Director, US
Operations, Innovus Research, Inc., Medford, MA, UA |
| MI1 |
HANDLING MISSING DATA IN
STOCHASTIC COST-EFFECTIVENESS ANALYSIS: THE IMPACT OF IMPUTATION METHODS ON
ESTIMATES OF THE PHYSICAL QUANTITIES OF MEDICAL CARE RESOURCE USE
Bell TJ1, Liu J1, Backhouse M2, 1Research Triangle Institute,
Raleigh-Durham, NC, USA; 2Research Triangle Institute, Manchester, UK |
| MI2 |
COST-EFFECTIVENESS VS.
COST-UTILITY ANALYSIS: DOES ADJUSTING FOR HEALTH-RELATED QUALITY OF LIFE
REALLY MATTER?
Tengs TO, Lin TH, Health Priorities Research Group, University of
California, Irvine, CA, USA |
| MI3 |
IMPORTANCE OF CONSIDERING
SENSITIVITY AND SPECIFICITY OF SCREENING METHODS IN HEALTH ECONOMIC ANALYSES
OF DIABETIC NEPHROPATHY SCREENING POLICIES
Palmer AJ, Roze S, CORE Center for Outcomes Research, Basel, BS, Switzerland |
| MI4 |
THE DANGER OF IGNORING
POPULATION HETEROGENEITY WHEN MARKOV MODELS ARE USED FOR COST EFFECTIVENESS
ANALYSIS
Zaric GS, University of Western Ontario, London, ON, Canada |
|
HEALTH POLICY – COMPLIANCE ISSUES |
|
Moderator:
Joseph DiCesare RPh, MPH, Executive Director, Outcomes Research, Novartis Pharmaceuticals, East Hanover, NJ, USA |
| HP1 |
SUB-OPTIMAL STATIN
COMPLIANCE IN PRIMARY AND SECONDARY PREVENTION POPULATIONS: SHOULD WE TARGET
PATIENTS WITH THE MOST TO GAIN?
Ellis JJ1, Erickson SR1, Stevenson JG1, Bernstein SJ2, Stiles RA3, Fendrick
AM1, 1University of Michigan, Ann Arbor, MI, USA; 2Veterans Affairs Medical
Center, Ann Arbor, MI, USA; 3Vanderbilt University, Nashville, TN, USA
|
| HP2 |
IS IT COST-EFFECTIVE
TO IMPROVE COMPLIANCE WITH LIPID-LOWERING THERAPY?
Benner JS1, Ganz DA1, Weinstein MC2, Neumann PJ2, Glynn RJ1, Avorn J1,
1Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA;
2Harvard School of Public Health, Boston, MA, USA |
HP3 |
IMPROVING THE SAFETY
OF AMIODARONE IN THE CONGESTIVE HEART FAILURE POPULATION: BASELINE
ASSESSMENT OF COMPLIANCE WITH NATIONAL GUIDELINES IN A LARGE CHF CLINIC
Just VL, Williams RE, Evanston Northwestern Healthcare, Evanston, IL, USA |
| HP4 |
THE IMPACT OF
ADHERENCE TO OSTEOPOROSIS THERAPY ON FRACTURE RATES IN ACTUAL PRACTICE
Caro J1, Huybrechts K1, Ishak K2, Naujoks C3, 1Caro Research Institute,
Concord, MA, USA; 2Caro Research Institute, Dorval, QC, Canada; 3Novartis
Pharma AG, Basel, Switzerland |
|
CARDIOVASCULAR DISEASE/DISORDERS II |
|
Moderator: Gerry
Oster PhD,
Vice President, Policy Analysis,
Inc., Brookline, MA, USA |
| CV5 |
COST-EFFECTIVENESS
OF STATINS IN PRIMARY PREVENTION OF CHD
Wendland G1, Lauterbach K2, 1Cologne, NW, Germany; 2University
of Cologne, Cologne, Germany |
| CV6 |
COMPARING RECENT
CARDIOVASCULAR MEDICATIONS USING AN NNT MODEL
Caro J1, Ishak K2, Caro I2, Migliaccio-Walle K1, 1Caro Research
Institute, Concord, MA, USA; 2Caro Research Institute, Dorval,
QC, Canada |
| CV7 |
COST-EFFECTIVENESS
OF ADENOSINE AND DIPYRIDAMOLE IN TECHNETIUM-99M SESTAMIBI SINGLE PHOTON
COMPUTED TOMOGRAPHY IMAGING
Reddy P1, Coleman CI1, Ahlberg AW2, Aoun G2, Vellasamy M2,
McGill C2, Alexander L2, Fleming RA2, Heller GV2, 1University of
Connecticut, Storrs, CT, USA; 2Hartford Hospital, Hartford, CT, USA |
| CV8 |
FORMULARY DECISIONS:
THE USE OF MULTI-ATTRIBUTE ANALYSIS – A BASELINE CASE STUDY OF PERCUTANEOUS
TRANSLUMINAL CORONARY ANGIOPLASTY
Hess GP1, Kroch E2, Yaffe K3, Barbaccia JG4, 1Wayne, PA, USA;
2CareScience, Philadelphia, PA, USA; 3Norristown, PA, USA; 4Washington
Hospital Center, Washington, DC, USA |
|
CANCER |
|
Moderator: Joseph
Lipscomb, Chief, Outcomes Research
Branch, National Cancer Institute, Bethesda, MD, USA |
|
CN1 |
ECONOMIC EVALUATION OF CAPECITABINE-DOCETAXEL COMBINATION TREATMENT OF
METASTATIC BREAST CANCER: A MICRO-SIMULATION STUDY
Hornberger J1, Jamieson C2, O’Shaughnessy J3, 1Acumen, LLC and
Stanford University School of Medicine, Burlingame, CA, USA; 2Roche
Pharmaceuticals, Palo Alto, CA, USA; 3US Oncology-Baylor-Sammons Cancer
Center, Dallas, TX, USA |
|
CN2 |
COST-UTILITY ANALYSIS OF LHRH AGONISTS IN THE TREATMENT OF METASTATIC
PROSTATE CANCER
Hemels M1, Iskedjian M2, Iscoe N3, Fleshner N4, Einarson T1,
1University of Toronto, Toronto, ON, Canada; 2Pharmideas Research and
Consulting Inc, Oakville, ON, Canada; 3Toronto-Sunnybrook Regional Cancer
Centre, Toronto, ON, Canada; 4Sunnybrook and Women's Health Sciences Center,
Toronto, ON, Canada |
|
CN3 |
BEHIND THE VEIL OF IGNORANCE: ASSESSMENT OF PREFERENCES AND UTILITIES FROM
MEN AT-RISK FOR PROSTATE CANCER
Bruner DW1, Hanlon A1, Sargent T1, Mazzoni S1, Raysor S1, Hanks G2,
1Fox Chase Cancer Center, Cheltenham, PA, USA; 2formerly from Fox Chase
Cancer Center, Philadelphia, PA, USA |
|
CN4 |
COMPARISON OF TREATMENT MODALITIES IN PROSTATE CANCER PATIENTS
Morris L, Margolis J, Henderson SC, von Allmen H, IMS HEALTH,
Plymouth Meeting, PA, USA |
|
|
9:30-10:00 AM |
Exhibits &
Poster Presentations
– Session II |
|
|
Coffee Breaks Sponsored by
Caro Research |
|
10:00-10:30AM |
Incoming Presidential
Address Peter Davey MD, FRCP,
2002-2003 ISPOR President & Head of Pharmacoeconomics, University of Dundee,
Dundee, Scotland, UK
Presentation:
2002 ISPOR Distinguished Service Awards
|
|
|
Presentation of the PhRMA Foundation 2002 Research Starter Grants in Health
Outcomes
Presented by: Del Persinger, President and CEO,
Pharmaceutical Research Manufacturers Association (PhRMA)
Awardees: Marc
Lipsitch Dphil, Harvard University, Department of Epidemiology, Boston,
MA, USA; Judith A. Shinogle PhD, University of
South Carolina, College of Pharmacy, Columbia, SC, USA;
Lisa A. Prosser PhD, Harvard Medical School, Department of Ambulatory
Care and Prevention, Boston, MA, USA
|
|
10:30-12:00 AM |
Second Plenary Session |
|
|
"THE RISE OF RISK
MANAGEMENT"
Recent trends in the withdrawal of drugs from the market highlight a new era
of risk control. The Food and Drug Administration (FDA) has publicly exclaimed
that traditional means of assuring safe use (e.g. product labels, dear health
professional letters) may not be sufficient to assure continued marketing of
pharmaceutical products. Rather, new risk management techniques may be
necessary to assure that drugs are used safely and effectively. This session
will discuss the FDA’s new philosophy of risk management as a public health
priority. It will also discuss alternative models for examining risk
management from an economic/public policy perspective. In addition, this
session will discuss an evolving role for outcomes researchers in the
development and evaluation of risks management mechanisms.
Moderator: Peter Neumann ScD, ISPOR Annual
Meeting Program Chair and Assistant Professor of Policy & Decision Sciences,
Harvard School of Public Health, Boston, MA, USA and
Louis A. Morris PhD, ISPOR Annual Meeting Plenary Session Chair and
President, Louis A. Morris & Associates, Dix Hills, NY, USA
"Cost-Effectiveness
Analysis in Health Policy"
Speaker: John D. Graham PhD, Administrator,
Office of Management and Budget, Washington, DC, USA
"Risk Management:
Issues for Outcomes Researchers"
Speaker: Janet Woodcock MD, Director, Center for
Drug Evaluation & Research, Food & Drug Administration, Rockville, MD, USA
Questions and Audience Discussion
|
|
12:00-1:30 PM |
Exhibits,
Poster Presentations – Session II and Lunch |
|
|
Lunch Sponsored by
Polidais LLC |
|
1:30-2:30 PM |
Concurrent Issues Panels (4
Sessions) |
|
|
Is $50,000/QALY High Enough for a US Benchmark?
Panel will debate the appropriateness of the use of quality adjusted life
years (QALYs) as common benefit measure of medical interventions. The
implications of setting a specific threshold level and whether the oft-quoted
$50,000/QALY threshold is a feasible benchmark for the US will be discussed.
Chair: A. Mark Fendrick MD, Associate Professor,
University of Michigan Medical Center, Ann Arbor, MI, USA
What’s Next for Outcomes Research in Asia?
This session will identify and discuss key issues of conducting
pharmacoeconomics and heath outcomes research in Asia. Also, the roles of
different players (government, academic, industry, etc) will be discussed.
Chair: Hong Li PhD, Associate Director,
Bristol-Myers Squibb, Wallingford, CT, USA
Medication Compliance: How Can It Be Included in
Pharmacoeconomic Studies?
Panelists will discuss compliance in the context of modeling clinical and
economic outcomes of care.
Chair: Joyce Cramer BS, Associate Research
Scientist, Yale University School of Medicine, West Haven, CT, USA
Using Health Economic and Other Outcomes Information to
Develop Sound Prescription Drug Plans: Practical or Improbable in the US?
Managed care and others are looking to pharmacoeconomic and outcomes research
in developing drug plans. Will different, more informed decisions result? What
are the obstacles?
Chair: Joanna Siegel ScD, Director, Research
Initiative in Clinical Economics, Agency for Healthcare Research & Quality,
Rockville, MD, USA
|
|
2:30-2:45 PM |
Break |
|
2:45-3:45 PM |
Concurrent Contributed Workshop
Presentations (8 sessions in 4 categories) |
|
|
|
Methodology Issues |
| WW19 |
METHODOLOGICAL ISSUES IN MEASURING AND INFLUENCING ANTIBIOTIC PRESCRIBING
IN HOSPITALS
Davey PG1, Ofori BD2, 1University of Dundee, Dundee, United
Kingdom; 2Ninewells Hospital and Medical School, Dundee, United Kingdom |
| WW20 |
METHODOLOGICAL CHALLENGES IN RETROSPECTIVE DATABASE STUDIES: STEPS FOR
GETTING IT RIGHT
Menzin J, Lang K, Boston Health Economics, Waltham, MA, USA |
| WW21 |
ISSUES IN
THE SPECIFICATION OF PERFORMANCE MEASURES: INSIGHTS FROM THE STUDY OF
CLINICALLY RELEVANT INDICATORS OF PHARMACOLOGIC THERAPY (THE SCRIPT
PROJECT)
Edward W, Kogut S, Massachusetts Peer Review Organization,
Inc, Waltham, MA, USA |
| WW22 |
PSYCHOMETRICS FOR THE NON-PSYCHOMETRICIAN
Fehnel SE, McLeod LD, RTI Health Solutions, Research
Triangle Park, NC, USA |
|
Health Policy |
| WW23 |
PAVING A
ROAD TO SUCCESS: HOW TO OBTAIN AN OUTCOMES RESEARCH FELLOWSHIP WITHIN THE
PHARMACEUTICAL INDUSTRY
Carter CT, Maio V, Pizzi L, Lofland J, Thomas
Jefferson University, Philadelphia, PA, USA |
| WW24 |
RISE OF
CONSUMERISM – UNDERSTANDING CONSUMER SOVEREIGNTY
Heissel A, Ethicon Endo-Surgery (Europe) GmbH, Norderstedt, Germany |
|
Design and Implementation |
| WW25 |
MEASURING
VALUE IN THE DRUG DEVELOPMENT PROCESS: HOW DO YOU KNOW IT IS THERE?
Paul JE1, Backhouse ME2, 1RTI Health Solutions, Research Triangle
Park, NC, USA; 2RTI Health Solutions, Manchester, United Kingdom |
| WW26 |
MAXIMIZING
THE SCIENTIFIC AND STRATEGIC VALUE OF PATIENT REGISTRIES
Trotter J, Larson L, Vreeland MG, Ovation Research Group, Highland
Park, IL, USA |
|
Practical Issues |
| WW27 |
EVALUATION
OF HEALTH ECONOMIC INFORMATION USED IN PROMOTION
Piault E, Cronin K, Mathieu J, Hu EJ, Burke LB, Food and Drug
Administration, Rockville, MD, USA |
|
|
3:45-4:00 PM |
Break |
|
4:00-5:30 PM |
Medical Device & Diagnostics
Forum |
|
|
"USING MEDICAL DEVICE AND
DIAGNOSTICS OUTCOMES RESEARCH TO SUPPORT HEALTH POLICY & REIMBURSEMENT
DECISIONS"
This Forum is coordinated by the ISPOR Medical Device and Diagnostics Council
(http://www.ispor.org/committees/advcouncils.asp)
FORUM PROGRAM |
|
4:00-4:45 PM |
USING OUTCOMES
RESEARCH STUDIES TO SUPPORT IMPROVED PRODUCTIVITY
Private payers are using HEDIS measurements to imply greater productivity to
employers. This presentation will focus on how outcomes research studies can
be used to support improved workplace productivity. |
|
4:00-4:10
|
Moderator: Pamela
Koo, Director, Global Reimbursement Policy Welch Allyn, Inc |
|
4:10-4:35 |
Speaker: Sean Sullivan, President & CEO, Institute for Health and Productivity
Management, Scottsdale, AZ, USA |
|
4:35-4:45 |
Questions and Answers |
|
4:45-5:30 PM |
HOW TO SUPPORT
REIMBURSEMENT OF OFF-LABEL USE OF MEDICAL DEVICES AND DIAGNOSTICS: WILL
OUTCOMES RESEARCH HELP?
During the diffusion of innovation process, new medical technologies are used
to treat or reduce symptoms in ways other than described on the labeling. This
presentation will focus on off-label use of medical and diagnostic
technologies, associated reimbursement issues, as well as research
opportunities to support reimbursement decisions. |
|
4:45-5:00 |
Moderators: Randel
Richner RN, MPH, Vice President,
Federal Affairs, Reimbursement and Outcomes Planning, Boston Scientific
Corporation, Natick, MA, USA
and Sarah Wells,
Boston Scientific Federal Affairs,
Washington, DC, USA |
|
5:00-5:20 |
Speaker: Stuart
Langbein Esq., Partner, Hogan &
Hartson L.L.P. Washington, DC, USA |
|
5:20-5:30 PM |
QUESTIONS AND ANSWERS |
|
4:00-5:30 PM |
Quality of Life Forum |
|
|
"Summary Measures Of
Population Health Status – WHO Cares?"
This Forum is coordinated by the ISPOR Quality of Life Special Interest Group
( http://www.ispor.org/sigs/sigsindex.asp)
Measuring health outcomes is a key component in establishing the
cost-effectiveness of any new therapy as well as the measurement of population
health. The World Health Organization (WHO) has setup new programmes to
describe and value health/health-related quality of life (HRQOL) for the
evaluation of healthcare. This work has serious implications for government
health agencies, the pharmaceutical industry and the wider research community.
Can there ever be a single common means of describing
health/HRQOL? How portable are concepts of health between countries? How are
they influenced by factors such as age, gender, education or ethnicity? Whose
values should count and do
values transcend countries? Is it meaningful to consider a single "world"
value set? If our governments listen to WHO on this agenda, ISPOR
members should be sufficiently well informed to be able to have their say too.
Moderator: Joyce
Cramer, Associate Research Scientist, Yale University School of Medicine, New
Haven, CT, USA
FORUM PROGRAM |
|
4:00-4:20 |
THE WHO MEASUREMENT OF
POPULATION HEALTH INITIATIVE
Speaker: Dean Jamison PhD, Senior Research Fellow, Division of
International Epidemiology and Populations Studies, Fogarty International
Center, National Institute of Health, Bethesda, MD USA
|
|
4:20-4:40 |
MEASURING HEALTH STATUS IN
NATIONAL POPULATION SURVEYS: US EXPERIENCE AND ISSUES RELEVANT TO THE WHO
INITIATIVE
Speaker: Edward Sondik PhD, Director, National
Center for Health Statistics, Center for Disease Control, Hyattsville, MD, USA |
|
4:40-5:00 |
USING POPULATION HEALTH
STATUS MEASURES IN CLINICAL STUDIES: INFORMATIONAL AND INTERNATIONAL
IMPLICATIONS
Speakers: Pennifer Erickson PhD, Co-founder,
O.L.G.A, State College, PA, USA and Diane Wild MSc, Partner, Oxford Outcomes,
Headington, Oxford, UK |
|
5:00-5:20 |
PANEL AND AUDIENCE DISCUSSION |
|
5:20-5:30 |
RAPPORTEUR
Presenter: Paul Kind Mphil, Senior Research
Fellow, Outcomes Research Group, Centre for Health Economics, University of
York, York, UK
|
|
4:00-5:30 PM |
Clinical Practice Forum |
|
|
"Using
Cost-Effectiveness & Outcomes Research To Increase A Patient's Access To New
Drugs: Case Study In Diabetic Complications"
What Can We Learn? How Can We Serve Patients Better?
This Forum is coordinated by the ISPOR Clinical Practice Special Interest
Group (http://www.ispor.org/sigs/cp.htm).
This forum will focus on the use of
cost-effectiveness and outcomes research information to determine the value of
new treatment options in clinical practice. Information needed by the
clinician to assure the best care for the patient will be discussed.
(This program qualifies for 2 hours [0.2 CME credits] Category II. This
program complies with the AMA’s definition of CME.)
|
|
|
FORUM PROGRAM |
|
4:00 – 4:15 PM |
WELCOME AND INTRODUCTION TO THE
ISPOR CLINICAL
PRACTICE SPECIAL INTEREST GROUP
Pamela Chavis MD, Chair, ISPOR Clinical Practice
Special Interest Group, and Associate Professor, Department of Ophthalmology,
Medical College of Virginia, Richmond, VA, USA |
|
4:15 – 4:35 PM |
THE ROLE OF OUTCOMES
RESEARCH IN CLINICAL DECISIONS
A. Mark Fendrick MD, Associate Professor,
University of Michigan Medical Center, Ann Arbor, MI, USA |
|
4:35 – 4:55 PM |
EPIDEMIOLOGY OF DIABETIC
RETINOPATHY
Stephen Schwartz MD, Assistant Professor, Department of Ophthalmology, Medical
College of Virginia, Richmond, VA, USA |
|
4:55 – 5:20 PM |
NEW TREATMENT
PARADIGMS FOR DIABETIC RETINOPATHY & MACULAR EDEMA
Matthew Sheetz MD, PhD, Clinical Research
Physician, Eli Lilly and Company, Indianapolis, IN, USA |
|
5:20 – 6:00 PM |
PANEL DISCUSSION AND
AUDIENCE PARTICIPATION
Pamela Chavis MD, Chair, ISPOR Clinical Practice
Special Interest Group, and Associate Professor, Department of Ophthalmology,
Medical College of Virginia, Richmond, VA, USA
|
|
5:30-6:00 PM |
ISPOR Quality of Life Special Interest Group
Meetings (followed by reception) |
|
5:30-6:00 PM |
ISPOR Business Meeting (followed by reception) |
|
6:00-7:00 PM |
Exhibits, Poster Presentations
- Session II & Closing Reception |
|
|
